First Trust NASDAQ Clean Edge Green Energy Idx Fd vs Smith & Nephew plc — how do they compare? First Trust NASDAQ Clean Edge Green Energy Idx Fd trades at $49.35, while Smith & Nephew plc trades at $27.72 (market cap $11.63B). The key difference: Smith & Nephew plc pays a 2.85% dividend while First Trust NASDAQ Clean Edge Green Energy Idx Fd pays none, and First Trust NASDAQ Clean Edge Green Energy Idx Fd is trading nearer its 52-week high, Smith & Nephew plc nearer its low. Which is the better fit depends on your goals.
| QCLN | SNN | |
|---|---|---|
Sector | Sector/Thematic | Health |
52-Week High | $68.47 | $38.53 |
52-Week Low | $37.69 | $27.80 |
Market Cap | — | $11.63B |
Enterprise Value | — | $14.66B |
Dividend Yield | — | 2.85% |
Signals from Pluang's Aura AI — not financial advice
QCLN trades at $50.57, up 2.31% today, with a bullish technical signal overall despite bearish moving averages. The ETF is positioned to benefit from global renewable energy acceleration driven by geopolitical tensions and rising data center power demand. Recent news highlights its sensitivity to U.S. political outcomes and federal clean energy policy, with historical outperformance ahead of midterm elections.
The outlook is supported by structural tailwinds in clean energy adoption, but risks include regulatory uncertainty and permit delays under current U.S. administration. Investment appeal hinges on policy continuity and execution of global renewable projects, with volatility expected around political developments.
Smith & Nephew (SNN) trades at $27.87, down 3.46% over 24 hours and near its 52-week low. The stock shows a bearish technical trend with mixed sentiment; recent earnings have mostly beaten expectations, but Q2 2026 revenue growth missed and guidance was cut. Fundamentals are solid with revenue rising to $6.16B in 2025 and net income margin improving to 10.08%, though debt levels have increased. The company faces competitive pressures in key markets like U.S. Orthopaedics.
Outlook is cautious: valuation ratios like P/E of 18.96 are reasonable, but analyst consensus is Hold (65%) due to execution risks and CFO departure. Opportunities include innovation in surgical robotics and new product launches, but investors should monitor U.S. market weakness and debt management for sustained recovery.
Trailing returns across standard periods
QCLN invests in U.S.-listed companies engaged in clean energy technologies. It focuses on solar power, wind, electric vehicles, and energy storage, with major holdings in firms like Tesla, ON Semiconductor, and Rivian.
Read more on QCLN →Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →